Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 8/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988478 | 0.86 | TRPV4 (0.36) | TSHRARTRPV4KDM5ACYP11B1 | |
| SCHEMBL13748000 | 0.82 | TRPV4 (0.38) | ARTRPV4CYP11B1CYP11B2MAOA | |
| SCHEMBL13799262 | 0.82 | TSHR (0.41) | TSHRARKDM5ACYP11B1CYP11B2 | |
| SCHEMBL16132831 | 0.79 | AR (0.39) | ARTRPV4KDM5ACYP11B1CYP11B2 | |
| SCHEMBL410450 | 0.77 | TSHR (0.44) | TSHRARTRPV4EGLN2CYP11B1 | |
| SCHEMBL9945875 | 0.77 | LMNA (0.34) | — | |
| SCHEMBL13748003 | 0.77 | IMPDH2 (0.50) | ARMAOAMAOBALDH1A1IMPDH2 | |
| SCHEMBL21937408 | 0.76 | AR (0.40) | TSHRARKDM5ACYP11B1CYP11B2 | |
| SCHEMBL12957943 | 0.75 | TSHR (0.43) | TSHRARTRPV4EGLN2CYP11B1 | |
| SCHEMBL16122059 | 0.73 | TRPV4 (0.37) | ARTRPV4CYP11B1CYP11B2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-9951071-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9409908-B2 | Dihydropyridone p1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | TSHR 3268/4885AR 3101/4885TRPV4 4030/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | TSHR 3734/4885AR 3518/4885TRPV4 4634/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | TSHR 3268/4885AR 3101/4885TRPV4 4030/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | TSHR 3268/4885AR 3101/4885TRPV4 4030/4885 |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | TSHR 3303/4885AR 3399/4885TRPV4 1066/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | TSHR 3268/4885AR 3101/4885TRPV4 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.